High-dose XXXX for selective @entity750 reuptake inhibitor-associated ejaculatory delay: open clinical trial.

@entity1 @entity323 @entity308 @entity7855 @entity750
BACKGROUND: Selective @entity750 reuptake inhibitor (SSRI)-induced ejaculatory delay is a common problem that has no treatment with established efficacy. @entity7855 is effective for @entity323 and appears to be safe at doses up to 200 mg. METHOD: We enrolled @entity1 who were in remission from @entity308 according to DSM-IV criteria and who reported that they had developed new-onset ejaculatory delay in the setting of SSRI treatment. Enrolled @entity1 were instructed to use 25 mg of @entity7855 1 hour prior to sexual activity on at least 2 occasions. If this was not effective for the ejaculatory delay, they were instructed to increase the dose progressively up to a maximum of 200 mg. We compared baseline sexual functioning to 2 phases of open treatment: low-dose phase ( @entity7855 25-100 mg) and high-dose phase ( @entity7855 150-200 mg). The primary outcome measure was a modified, self-report Clinical Global Impressions (CGI) scale that was specific for erectile (CGI-EF) and ejaculatory (CGI-EJF) aspects of sexual function. RESULTS: Twenty-one @entity1 (mean age = 56 years) with @entity308 ( @entity308 ) in remission and SSRI-associated ejaculatory delay enrolled in the study and received @entity7855 . At baseline, 14 of 21(67%) had comorbid @entity323 . At the low-dose phase follow-up assessment, 12 of 14 achieved full @entity323 remission, and 4 of 21 achieved ejaculatory delay remission. Sixteen @entity1 with persistent ejaculatory delay were eligible for the high-dose phase: 5 withdrew from the study, 4 increased to a maximum dose of 150 mg, and 6 increased to a maximum dose of 200 mg. The 1 @entity1 who had clinically significant @entity323 and ejaculatory delay reported improvement of both conditions after the high-dose phase. Of the 10 @entity1 who had ejaculatory delay without significant @entity323 and who chose to take high-dose @entity7855 , 9 reported a significant clinical improvement in ejaculatory delay (CGI-EJF improvement score of 1 or 2) and 7 achieved full remission (CGI-EJF severity score of 1 or 2 and CGI-EJF improvement score of 1 or 2). CONCLUSION: In this open clinical trial with @entity1 who had SSRI-induced ejaculatory delay, high-dose @entity7855 appeared to be effective in reducing ejaculatory latency.
